Fascinatingly, the in vivo stability, pharmacokinetics, and LAT1 tumor uptake of 2-α-methyl-L-phenylalanine analog remains unaffected when α-particle emitter astatine-211 (211At) is integrated to construct the therapeutic analog 2-[211At]-astato-α-methyl-L-phenylalanine ([211At]AAMP) 103. This evidence concerns the gene SLC7A5 and neoplasm.